Take­da strikes $500M+ deal for Cal­i­for­nia biotech's ALS pro­gram

Take­da is bet­ting more than half a bil­lion dol­lars on a Cal­i­for­nia biotech’s ap­proach to treat­ing amy­otroph­ic lat­er­al scle­ro­sis (ALS) and oth­er neu­rode­gen­er­a­tive dis­eases. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER